New drug The story usually begins with a tragic event.
Peter Ray is aware of this. Ray, who was born in the now-Zimbabwe, and is the son of a radiology technologist and mechanic, fled to South Africa with his family during the Zimbabwean War of Liberation. In 1980, he recalls making the trip in a convoy with armored vehicles. Ray, 8, was taught to use a machine-gun by a soldier as the sun beat down. His mother had to keep stopping. She was not feeling well.
Cape Town Doctors diagnosed her with cancer. Ray recalled going with her to the radiation treatment, hospital rooms and the colostomy bag. She was a beach lover, and loved walking along the shoreline where water meets land. It became harder to get her there. She would sometimes come home for a short time from the hospital and things seemed to get better. Ray became naive. Then, everything would crumble again. Surgery, radiation, chemotherapy—the treatments that were on the table in the 1980s—were soon exhausted. He promised to help her in some way as she was dying. He was only 13 years old.
Ray was a medical chemist. He studied first in South Africa and took out loans for his education. Then he went to the University of Liverpool. He worked for drug companies Across the UK on many projects. At 53 years old, he’s one of Recursion Pharmaceuticals’ lead drug developers. His mom’s promise is a constant thought in his mind. “It’s lived with me my whole life,” He says. “I need to get drugs on the market that impact cancer.”
It may also be motivated by the desire to prevent your tragedies happening again to others. The process is not easy. drug discovery The pace of life has been slow and grueling. First, chemists like Ray zero in on their target—usually a protein, a long string of amino acids coiled and folded upon itself. On their computer, they display a picture of the protein and observe it spinning in an empty black space. Then they note its curves and declivities, the places where molecules, like spaceships, can dock. They then try to construct the spaceship atom by atom.
Animation: Balarama Heller
Once the new molecule has been created, the chemists then send it to the biologistsThe test is done on live cells, in warm environments. Another tragedy is that many cells are killed for unknown reasons. The new drug does not work the way it was expected. They will need to make another and then another. This process can take years. Keith Mikule is a biologist at Insilico MedicineHe told me about his work at a drug firm. They couldn’t continue with their best molecule after five years because it was plagued by dangerous and unforeseen side effects. “There was a large team of chemists, a large team of biologists, thousands of molecules made, and no real progress,” “He said”
They may get lucky and discover a mouse-friendly molecule. Then they get to test it on a group of healthy humans, called a Phase I. trial. In phase II, if the volunteers remain healthy, they can give the drug to even more people with diseases in question. If the sick people don’t get sicker, they get a chance—phase III—to give it to more sick people, as many as they can find, as diverse a group as possible.
At every stage, there are many drugs that fail for reasons no one can understand. In the end, more than 90% of those who try to succeed fail. Asking drug-hunters if they ever succeeded in making a drug is a delicate, but cautious question. “It’s very rare,” Mikule is a man with a single drug to his name (niraparib) for the treatment of ovarian tumors. “We’re unicorns.”
